To identify potential molecular targets for CNOT7 on NK cells, we investigated the serum levels of LAIR-1, a pertinent inhibitory receptor expressed in a vast majority of NK cells (>90%) [29], and its high expression is associated with poor clinical outcomes in BC [30]. This evidence concerns the gene LAIR1 and breast cancer.